A Comparative Analysis of Nonconforming Product Control and CAPA Requirements in ISO 13485 and FDA 21 CFR Part 820

Nonconforming product control and Corrective and Preventive Action (CAPA) are critical for ensuring medical device quality. This paper provides a comparative analysis of ISO 13485:2016 and FDA 21 CFR Part 820, emphasizing their roles in safeguarding patient safety and facilitating continuous improvement in device manufacturing. Both standards outline robust procedures for detecting, documenting, and segregating nonconforming products to avert unintended use or distribution. Beyond detection, CAPA serves as a proactive framework to address root causes, reduce defect recurrence, and maintain compliance with regulatory expectations. The paper delves into the Non-Conforming Material Report (NCMR) process as a systematic tool to manage nonconformities, from initial identification to final disposition. It also discusses the broader business benefits of effective CAPA, including lowered operational costs, reduced risk of recalls, and bolstered public trust. By aligning their quality management systems with these regulatory requirements, manufacturers can ensure product reliability and preserve the safety of end users.